Movano Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Movano wird ein Gewinn- und Umsatzwachstum von 20.6% bzw. 94.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 37.9% pro Jahr wachsen soll.

Wichtige Informationen

20.6%

Wachstumsrate der Gewinne

37.9%

EPS-Wachstumsrate

Tech Gewinnwachstum	10.5%
Wachstumsrate der Einnahmen	94.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:MOVE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	16	-20	N/A	-15	1
12/31/2024	2	-26	N/A	-21	1
9/30/2024	1	-25	-23	-23	N/A
6/30/2024	1	-27	-25	-25	N/A
3/31/2024	1	-28	-24	-24	N/A
12/31/2023	N/A	-29	-26	-26	N/A
9/30/2023	N/A	-31	-27	-27	N/A
6/30/2023	N/A	-31	-27	-27	N/A
3/31/2023	N/A	-30	-25	-25	N/A
12/31/2022	N/A	-30	-25	-25	N/A
9/30/2022	N/A	-29	-24	-24	N/A
6/30/2022	N/A	-25	-21	-21	N/A
3/31/2022	N/A	-23	-19	-18	N/A
12/31/2021	N/A	-24	-17	-16	N/A
9/30/2021	N/A	-25	-14	-14	N/A
6/30/2021	N/A	-26	-14	-14	N/A
3/31/2021	N/A	-26	-12	-12	N/A
12/31/2020	N/A	-22	-11	-11	N/A
9/30/2020	N/A	-19	-10	-10	N/A
12/31/2019	N/A	-14	-8	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MOVE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MOVE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MOVE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MOVEDie Einnahmen des Unternehmens (94.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: MOVEDie Einnahmen des Unternehmens (94.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MOVE in 3 Jahren voraussichtlich hoch sein wird

Movano Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Movano Health Announces Completion of Clinical Study with Cuffless Rf Blood Pressure Device

Movano Inc. to Report Q3, 2024 Results on Nov 14, 2024

Movano Health Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Movano Health Announces the Immediate Availability of Its Evie Ring

We're A Little Worried About Movano's (NASDAQ:MOVE) Cash Burn Rate

New major risk - Financial position

Movano Inc. to Report Q2, 2024 Results on Aug 14, 2024

Movano Inc., Annual General Meeting, Jul 09, 2024

Movano Inc. announced delayed 10-Q filing

Movano Inc. to Report Q1, 2024 Results on May 15, 2024

Movano Inc. announced that it has received $24.128792 million in funding

Movano Inc. announced that it expects to receive $24.14411 million in funding

Movano Inc. announced that it expects to receive $23.985 million in funding

Movano Inc. announced delayed annual 10-K filing

Movano Health's Evie Ring's Pulse Oximeter Exceeds FDA Accuracy Guidelines in Movano Health's Second Hypoxia Trial

Movano Receives Non-Compliance Notice from Nasdaq

Movano Receives Non-Compliance Notice from Nasdaq

Movano Inc. has completed a Follow-on Equity Offering in the amount of $3.600008 million.

Movano Inc. to Report Q3, 2023 Results on Nov 14, 2023

Movano Inc. Appoints Fátima Rodriguez to Its Medical Advisory Board

High number of new and inexperienced directors

Movano (NASDAQ:MOVE) Will Have To Spend Its Cash Wisely

Movano Health Announces the Formation of its Medical Advisory Board

Movano Inc. to Report Q2, 2023 Results on Aug 14, 2023

New minor risk - Share price stability

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Movano's (NASDAQ:MOVE) Cash Burn Situation

Can Movano (NASDAQ:MOVE) Afford To Invest In Growth?

Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely for Women

Movano Inc. to Report Q3, 2022 Results on Nov 14, 2022

We Think Movano (NASDAQ:MOVE) Needs To Drive Business Growth Carefully

Movano Inc. Announces Beta Program with Stanford University to Advance the Development of Comprehensive Health Data Monitoring for its Wearable Ring Solution

Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring in Initial Hypoxia Study; Company Eyes FDA Submission

We Think Movano (NASDAQ:MOVE) Needs To Drive Business Growth Carefully

Movano Inc. Completes Functional Testing of Smallest Ever Custom mmWave Sensor Designed for Non-Invasive Glucose and Cuffless Blood Pressure Monitoring

Less than half of directors are independent

Movano Inc. to Report Q1, 2022 Results on May 12, 2022

Less than half of directors are independent

Movano Inc Appoints Nan Kirsten Forte to Its Board of Directors

Movano Inc. Announces Completion of its Second Glucose Pilot Study

Movano Strengthens Intellectual Property for its Non-Invasive Sensor Technology with Three New U.S. Patents

Movano Completes Blood Pressure Study with 110 Participants

Movano Unveils Smart Ring Designed for Women Seeking More Approachable Health Insights

We Think Movano (NASDAQ:MOVE) Can Afford To Drive Business Growth

Companies Like Movano (NASDAQ:MOVE) Are In A Position To Invest In Growth

Health tech company Movano to join Russell Microcap Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken